OBJECTIVES: With the internationalization of clinical trial programs, there is an increased need to translate and culturally adapt patient-reported outcome (PRO) measures. Although guidelines for good practices in translation and linguistic validation are available, the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Task Force identified a number of areas where they felt that further discussion around methods and best practices would be beneficial. The areas identified by the team were as follows: 1) the selection of the languages required for multinational trials; 2) the approaches suggested when the same language is required across two or more countries; and 3) the assessment of measurement equivalence to support the aggregation of data from different countries. METHODS: The task force addressed these three areas, reviewed the available literature, and had multiple discussions to develop this report. RESULTS: Decision aid tools have also been developed and presented for the selection of languages and the approaches suggested for the use of the same language in different countries. CONCLUSION: It is hoped that this report and the decision tools proposed will assist those involved with multinational trials to 1) decide on the translations required for each country; 2) choose the approach to use when the same language is spoken in more than one country; and 3) choose methods to gather evidence to support the pooling of data collected using different language versions of the same tool.
OBJECTIVES: With the internationalization of clinical trial programs, there is an increased need to translate and culturally adapt patient-reported outcome (PRO) measures. Although guidelines for good practices in translation and linguistic validation are available, the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Task Force identified a number of areas where they felt that further discussion around methods and best practices would be beneficial. The areas identified by the team were as follows: 1) the selection of the languages required for multinational trials; 2) the approaches suggested when the same language is required across two or more countries; and 3) the assessment of measurement equivalence to support the aggregation of data from different countries. METHODS: The task force addressed these three areas, reviewed the available literature, and had multiple discussions to develop this report. RESULTS: Decision aid tools have also been developed and presented for the selection of languages and the approaches suggested for the use of the same language in different countries. CONCLUSION: It is hoped that this report and the decision tools proposed will assist those involved with multinational trials to 1) decide on the translations required for each country; 2) choose the approach to use when the same language is spoken in more than one country; and 3) choose methods to gather evidence to support the pooling of data collected using different language versions of the same tool.
Authors: S J Bartlett; A K Gutierrez; A Butanis; V P Bykerk; J R Curtis; S Ginsberg; A L Leong; A Lyddiatt; W B Nowell; A M Orbai; K C Smith; C O Bingham Journal: Qual Life Res Date: 2018-05-24 Impact factor: 4.147
Authors: Christopher B Forrest; Katherine B Bevans; Carole Tucker; Anne W Riley; Ulrike Ravens-Sieberer; William Gardner; Kathleen Pajer Journal: J Pediatr Psychol Date: 2012-02-23
Authors: Bryce B Reeve; Kathleen W Wyrwich; Albert W Wu; Galina Velikova; Caroline B Terwee; Claire F Snyder; Carolyn Schwartz; Dennis A Revicki; Carol M Moinpour; Lori D McLeod; Jessica C Lyons; William R Lenderking; Pamela S Hinds; Ron D Hays; Joanne Greenhalgh; Richard Gershon; David Feeny; Peter M Fayers; David Cella; Michael Brundage; Sara Ahmed; Neil K Aaronson; Zeeshan Butt Journal: Qual Life Res Date: 2013-01-04 Impact factor: 4.147
Authors: Carole A Tucker; Katherine B Bevans; Rachel E Teneralli; Ashley Wilder Smith; Heather R Bowles; Christopher B Forrest Journal: Pediatr Phys Ther Date: 2014 Impact factor: 3.049
Authors: Ulrike Ravens-Sieberer; Janine Devine; Katherine Bevans; Anne W Riley; Jeanhee Moon; John M Salsman; Christopher B Forrest Journal: J Clin Epidemiol Date: 2013-12-02 Impact factor: 6.437